Allarity Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 5, 2024
ALLR$0.94-2.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
See the Exhibit Index to this Quarterly Report immediately below and before the signature page hereto, which Exhibit Index is incorporated by reference as if fully set forth herein.
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| Exhibit Number | Exhibit Description | Form | File No. | Exhibit | Filing Date | Filed Herewith |
| 3.1 | Certificate of Incorporation | S-4 | 333-258968 | 3.1 | August 20, 2021 | |
| 3.2 | Certificate of Amendment to the Certificate of Incorporation of Allarity Therapeutics, Inc. | S-4/A | 333-259484 | 3.3 | September 29, 2021 | |
| 3.3 | Second Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. | 8-K | 001-41160 | 3.1 | March 20, 2023 | |
| 3.4 | Third Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. | 8-K | 001-41160 | 3.1 | March 24, 2023 | |
| 3.5 | Fourth Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. | 8-K | 001-41160 | 3.1 | June 28, 2023 | |
| 3.6 | Fifth Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. | 8-K | 001-41160 | April 4, 2024 | ||
| 3.7 | Specimen Common Stock Certificate of Allarity Therapeutics, Inc. | S-4/A | 333-259484 | 4.1 | September 29, 2021 | |
| 3.8 | Amended and Restated Bylaws of Allarity Therapeutics, Inc. | S-4/A | 333-259484 | 3.4 | October 18, 2021 | |
| 3.9 | Amendment No. 1 to Amended and Restated Bylaws of Allarity Therapeutics, Inc. | 8-K | 001-41160 | 3.1 | July 11, 2022 | |
| 10.1 | First Comprehensive Amendment to At-The-Market Issuance Sales Agreement, dated May 17, 2024 | 8-K | 001-41160 | 10.1 | May 21, 2024 | |
| 10.2† | Management Services Agreement, effective as of June 1, 2024 | 8-K | 001-41160 | 10.1 | June 6, 2024 | |
| 31.1 | Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act | X | ||||
| 31.2 | Certifications of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act | X | ||||
| 32.1* | Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act | X | ||||
| 32.2* | Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act | X | ||||
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | ||||
| 101PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X | ||||
| 104* | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | — | ||||
| + | Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. |
|---|---|
| † | Indicates management contract or compensatory plan or arrangement. |
| * | Furnished herewith. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.